FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 44.e1-44.e7

  Lima, Luís ^a,b,c,d   Ferreira, José A ^a,e   Tavares, Ana ^a   Oliveira, Daniela ^a   Morais, António ^a   Videira, Paula A ^f   Medeiros, Rui ^a,b,d,g   Santos, Lúcio ^a,g  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^d LPCC   (Portugal)

^e UNIVERSITY OF AVEIRO   (Portugal)

^f UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^g UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

BCG immunotherapy; Bladder cancer; Fas FasL; Polymorphisms; Predictive markers

Indexed keywords

BCG VACCINE; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PHARMACOLOGICAL BIOMARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNIZATION; CONTROLLED STUDY; CYSTOSCOPY; DNA EXTRACTION; DNA POLYMORPHISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; FASL GENE; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

BCG IMMUNOTHERAPY; BLADDER CANCER; FAS/FASL; POLYMORPHISMS; PREDICTIVE MARKERS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; BCG VACCINE; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84890794225     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.05.009     Document Type: Article

References (30)

1. Ehrenschwender M., Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol 2009, 647:64-93.
2. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373(6513):444-448.
3. Radoja S., Saio M., Frey A.B. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol 2001, 166(10):6074-6083.
4. Chopin D., Barei-Moniri R., Maille P., Le Frere-Belda M.A., Muscatelli-Groux B., Merendino N., et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 2003, 162(4):1139-1149.
5. Houston A., O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004, 4:321-326.
6. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997, 34(8-9):577-582.
7. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003, 170(1):132-138.
8. Zhang Z., Qiu L., Wang M., Tong N., Li J. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009, 17(10):1294-1303.
9. Zhang Z., Xue H., Gong W., Wang M., Yuan L., Han S. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009, 30(3):487-493.
10. Li C., Wu W., Liu J., Qian L., Li A., Yang K., et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006, 16(4):245-251.
11. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bohle A., Palou-Redorta J., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59(6):997-1008.
12. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168(5):1964-1970.
13. Alexandroff A.B., Nicholson S., Patel P.M., Jackson A.M. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2010, 2(4):551-560.
14. Lima L., Dinis-Ribeiro M., Longatto-Filho A., Santos L. Predictive biomarkers of bacillus calmette-guerin immunotherapy response in bladder cancer: where are we now?. Adv Urol 2012, 2012:232609.
15. Ahirwar D.K., Manchanda P.K., Mittal R.D., Bid H.K. BCG response prediction with cytokine gene variants and bladder cancer: where we are?. J Cancer Res Clin Oncol 2011, 137(12):1729-1738.
16. Zuiverloon T.C., Nieuweboer A.J., Vekony H., Kirkels W.J., Bangma C.H., Zwarthoff E.C. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012, 61(1):128-145.
17. Brandau S., Suttmann H., Riemensberger J., Seitzer U., Arnold J., Durek C., et al. Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 2000, 6(9):3729-3738.
18. Jinesh G.G., Chunduru S., Kamat A.M. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL. J Leukoc Biol 2012, 92(1):233-244.
19. Lima L., Silva J., Amaro T., Morais A., Lopes C., Medeiros R., et al. IL-4 and TNF-alpha polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development. Urol Int 2011, 87(4):457-463.
20. Lima L., Morais A., Lobo F., Calais-da-Silva F.M., Calais-da-Silva F.E., Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2008, 11(1):94-98.
21. Prescott S., Jackson A.M., Hawkyard S.J., Alexandroff A.B., James K. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis 2000, 31(Suppl. 3):S91-S93.
22. Videira P.A., Calais F.M., Correia M., Ligeiro D., Crespo H.J., Calais F., et al. Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009, 74(4):944-950.
23. Mehmut M., Takeda K., Abe M., Ogata H., Hirose S., Okumura K., et al. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guerin treatment. Urol Int 2005, 75(1):80-87.
24. Sun T., Zhou Y., Li H., Han X., Shi Y., Wang L., et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005, 202(7):967-974.
25. Farragher S.M., Tanney A., Kennedy R.D., Paul Harkin D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 2008, 130(3):435-445.
26. Stewart G.D., Baird J., Rae F., Nanda J., Riddick A.C., Harrison D.J. Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature. Int Urol Nephrol 2011, 43(4):961-967.
27. Gangwar R., Mittal R.D. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol 2010, 29(7):349-356.
28. Saint F., Salomon L., Quintela R., Cicco A., Hoznek A., Abbou C.C., et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003, 43(4):351-360. [discussion 360-1].
29. Ajili F., Manai M., Darouiche A., Chebil M., Boubaker S. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin immunotherapy. Ultrastruct Pathol 2012, 36(5):320-324.
30. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. BJU Int 2002, 89(7):671-680.